探讨阿托伐他汀联合缬沙坦对冠心病患者冠状动脉病变程度及对患者血清脂蛋白、C反应蛋白水平的影响

摘要

Objective To investigate the effects of Atorvastatin Combined with valsartan on the degree of coronary artery lesion and the level of serum lipoprotein and C reactive protein in patients with coronary heart disea.Methods 95 cases of patients with coronary heart disease from September 2015 to September 2016 in our hospital were randomly divided into observation group and control group,the control group were treated with atorvastatin,observation group of patients in the control group patients on the basis of the combination of valsartan treatment,severity of coronary artery disease,serum lipid and protein levels in patients with C reaction protein levels before and after treatment were compared between two groups.Results After treatment,the patients in the observation group were fibrous plaque,calcified plaque,lipid plaque,mixed plaque were significantly decreased,and lower than that of control group,and control group before and after treatment of fibrous plaque,calcified plaque had no obvious change after treatment,the observation group were HDL,LDL,TG,TC were(2.12±1.01),3.27±0.94),(1.53±0.98),(3.35±1.78)was significantly higher than the control group,the difference was significant,2 months after treatment,3 months to observe the levels in patients with C reactive protein were(10.27±1.78)and(7.26±2.63)was significantly lower than the control group with significant difference,with statistical significance(P<0.05).Conclusion Atorvastatin Combined with valsartan can help to reduce the coronary plaque,regulate lipid metabolism,reduce the level of C reactive protein.%目的 探讨阿托伐他汀联合缬沙坦对冠心病患者冠状动脉病变程度、血清脂蛋白、C反应蛋白的影响.方法 选择2015年9月～2016年9月期间在临海市第二人民医院诊断为冠心病患者95例,按随机数字表法分为观察组和对照组,对照组患者給予阿托伐他汀,观察组患者在对照组患者治疗的基础上联合缬沙坦治疗,对比2组患者治疗前后冠状动脉病变程度、患者血清脂蛋白水平及C反应蛋白水平.结果 治疗后观察组患者纤维斑块、钙化斑块、脂质斑块、混合斑块均有明显下降,且低于对照组患者,而对照组患者纤维斑块、钙化斑块治疗前后无明显变化,治疗后观察组患者HDL、LDL、TG、TC分别为(2.12±1.01)、(3.27±0.94)、(1.53±0.98)、(3.35±1.78)明显优于对照组患者,差异有统计学意义(P<0.05),治疗后2个月、3个月观察组患者C反应蛋白水平分别为(10.27±1.78)、(7.26±2.63)明显低于对照组患者,差异有统计学意义( P <0.05).结论 阿托伐他汀联合缬沙坦有助于减少冠脉斑块、调节脂代谢、降低C反应蛋白水平.